ly deﬁned.
PAD primarily results from atherosclerotic occlusion
of the arteries supplying the lower extremity. Consequently, management of asymptomatic PAD should be
directed at accepted risk factor modiﬁcation for patients
with atherosclerosis. Pharmacologic strategies with
proven beneﬁt for symptomatic PAD have been empirically applied to the treatment of the asymptomatic PAD
population. However, as noted below, certain pharmacologic interventions have failed to show beneﬁ